Welcome to CSNpharm! For Research Use Only!
FGFR
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN21277 | Tyrosine kinase-IN-1 | 705946-27-6 | Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. |
| CSN33144 | E7090 | 1622204-21-0 | Tasurgratinib is a novel selective inhibitor of fibroblast growth factor receptors, that displays potent anti-tumor activity. |
| CSN18656 | Sulfatinib | 1308672-74-3 | Sulfatinib is an inhbitor of KDR and FGFR1 with IC50 values of 0.021 M and 0.053 M respectively. It also shows inhibition of hERG (IC50 6.8 M). |
| CSN20031 | (Z)-Orantinib | 210644-62-5 | SU6668 is a cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFR, VEGFR2 (Flk-1KDR), FGFR1 activity in vitro (IC50 0.01, 0.1, 3.9, and 3.8 M, respectively) and PDGFVEGFbFGF-mediated angiogenesis and tumor development. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target serthr kinases Aurora A, Aurora B, TBK1 (NAKT2K), and AMPK (IC50 0.85, 0.047, 1.4, and 1.8 M, respectively), as well as non-receptor TKs Lyn and Yes (IC50 4.3 and 5.8 M, respectively). |
| CSN15810 | SSR128129E | 848318-25-2 | SSR128129E is an allosteric modulator of FGFR by binding to the extracellular FGFR domain |
| CSN18466 | SSR128129E free acid | 848463-13-8 | SSR128129E free acid is a multi-FGFR blocker with allosteric properties and inhibits FGFR signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding |
| CSN22605 | S49076 HCl | 1265966-31-1 | S49076 hydrochloride is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 <20 nM. |
| CSN26937 | Rogaratinib | 1443530-05-9 | Rogaratinib is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. |
| CSN20388 | PRN1371 | 1802929-43-6 | PRN1371 is an irreversible covalent FGFR inhibitor used for the treatment of solid tumor |
| CSN21067 | Ponatinib hydrochloride | 1114544-31-8 | Ponatinib is a multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src respectively. |
| CSN26440 | Pemigatinib | 1513857-77-6 | Pemigatinib, also known as INCB054828, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. FGFR inhibitor INCB054828 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. |
| CSN12916 | PD173074 | 219580-11-7 | PD173074 is a potent FGFR1 inhibitor with IC50 of 25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM 1000-fold selective for FGFR1 than PDGFR and c-Src |
| CSN13927 | PD-166866 | 192705-79-6 | PD 166866 is a selective FGFR tyrosine kinase inhibitor with an IC50 of 524 nM |
| CSN23025 | PD0166285 dihydrochloride | 212391-63-4 | PD 166285 inhibited Src nonreceptor tyrosine kinase, fibroblast growth factor receptor-1, epidermal growth factor receptor and platelet-derived growth factor receptor beta subunit (PDGFR-beta), tyrosine kinases with half-maximal inhibitory potencies (IC50 values) of 8.4 +/- 2.3 nM (n = 6), 39.3 +/- 2.8 nM (n = 16), 87.5 +/- 13.7 nM (n = 6) and 98.3 +/- 7.9 nM (n = 16), respectively. |
| CSN23024 | PD-161570 | 192705-80-9 | PD 161570 is a selective FGFR inhibitor with IC50 of 40 nM. |
| CSN25230 | ODM-203 | 1430723-35-5 | ODM-203 is a selective inhibitor of FGFR and VEGFR with IC50 values of 11, 16, 6, 35nM for recombinant FGFR1-4 and 26, 9, 5nM for VEGFR1-3, respectively. |
| CSN22060 | MRX-2843 | 1429882-07-4 | MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3. |
| CSN16111 | LY2874455 | 1254473-64-7 | LY2874455 is a pan-FGFR inhibitor with IC50 of 28 nM 26 nM 64 nM and 6 nM for FGFR1 FGFR2 FGFR3 and FGFR4 respectively and also inhibits VEGFR2 activity with IC50 of 7 nM |
| CSN18841 | H3B-6527 | 1702259-66-2 | H3B-6527 acts as a selective FGFR4 inhibitor IC50 12 nM over FGFR1-3 |
| CSN13938 | FIIN-3 | 1637735-84-2 | FIIN-3 is an irreversible inhibitor of FGFR1-4 with IC50s of 13 21 31 and 35 nM respectively |
| CSN13937 | FIIN-2 | 1633044-56-0 | FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 31 43 27 and 45 nM respectively |
| CSN22818 | FIIN 1 HCl | 1779796-29-0 | FIIN 1 HCl is a potent, irreversible FGFR inhibitor with Kds of 2.8, 5.4, 6.9 and 120 nM for FGFR1, FGFR3, FGFR2 and FGFR4 respectively. |
| CSN18853 | FGFR4-IN-1 | 1708971-72-5 | FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 07 nM |
| CSN20012 | FGFR4 Inhibitor C(-)-11 | 2020395-38-2 | FGFR4 inhibitor C--11 is a highly potent FGFR4 inhibitor with selectivity over FGFR1 with good stability and CYP inhibition |
| CSN19155 | Futibatinib | 1448169-71-8 | FGFR-IN-1 is a potent and highly selective FGFR inhibitor used for antitumor treatment |
| CSN19757 | Roblitinib | 1708971-55-4 | FGF401 an inhibitor of human fibroblast growth factor receptor 4 FGFR4 IC50 11 nM has potential antineoplastic activity |
| CSN17720 | Erdafitinib | 1346242-81-6 | Erdafitinib inhibits FGFR1 pIC50 9 FGFR2 pIC50 85 FGFR3 pIC50 85 and FGFR4 pIC50 825 and it is a quinoxaline derivative compound |
| CSN20555 | Derazantinib | 1234356-69-4 | Derazantinib is a fibroblast growth factor receptor FGFR inhibitor that has antitumor activity |
| CSN12423 | Danusertib | 827318-97-8 | Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. |
| CSN17224 | Zoligratinib | 1265229-25-1 | CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. |
| CSN13925 | BLU9931 | 1538604-68-0 | BLU9931 is an inhibitor of FGFR4 with IC50 of 3 nM and is less potent for FGFR1/2/3 (IC50 > 150 nM). |
| CSN18780 | Fisogatinib | 1707289-21-1 | BLU-554 is a selective inhibitor of FGFR4 with the IC50 of 5 nM |
| CSN17679 | Infigratinib phosphate | 1310746-10-1 | BGJ398 Phosphate is a selective and potent inhibitor of FGFRs with IC50 values of 1nM for FGFR11-3 and 60nM for FGFR4, as well as 4.9nM for FGFR3-K650E mutant. |
| CSN16144 | Infigratinib | 872511-34-7 | BGJ-398 is a selective, pan-specific FGFR inhibitor with IC50 of 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively and > 40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. |
| CSN12890 | AZD4547 | 1035270-39-3 | AZD4547 is a selective FGFR inhibitor targeting FGFR123 with IC50 of 02 nM25 nM18 nM with weaker activity against FGFR4 VEGFR2 KDR and little activity observed against IGFR CDK2 and p38 |
| CSN19705 | ASP5878 | 1453208-66-6 | ASP5878 is a selective FGFR inhibitor to treat FGFR3-dependent urothelial cancer with or without chemoresistance |
| CSN26650 | ARQ 069 | 1314021-57-2 | and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC50s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner[1]. |
| CSN22608 | Alofanib | 1612888-66-0 | Alofanib is a selective and allosteric inhibitor of FGFR2 with potential antitumor activity |
| CSN12169 | Tyrphostin AG1296 | 146535-11-7 | AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR. It also inhibits FGFR and c-Kit with IC50 of 12.3 μM and 1.8 μM in Swiss 3T3 cells. |
| CSN18610 | EOC317 | 939805-30-8 | ACTB-1003 is a potent inhibitor of FGFR1 with IC50 10 nM in FGFR-1 biochemical assay |
| CSN26199 | SKLB 610 | 1125780-41-7 | |
| CSN33244 | Methyl 7-chloro-4-(4-methoxybenzyl)-2-methyl-5-oxo-4,5-dihydro-2H-pyrazolo[4,3-b]pyridine-6-carboxylate | 2338863-43-5 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
